Health
Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients
Philips iFR technology October 29, 2025 3-Year data from the largest global trial to date using Class I, Level A iFR in heart attack patients shows treating additional stenoses in the same procedure showed no significant difference in major outcomes compared with waiting for follow-upAdditional results from the ILIAS ANOCA study highlight the sustained benefits of physiology-guided assessment and tailored medical therapy for patients with angina and no obstructive coronary arteries Amsterdam, th
About this update from Koninklijke Philips N.v.
[{"type":"image","alt":"Royal Philips","displaySize":"","headline":null,"caption":"Royal Philips","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/e89b2492268f247076ffcde3cdf98919"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gAicZ00NXenNt1pULlYKVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/e89b2492268f247076ffcde3cdf98919","width":300,"height":55}},"lazy":false},{"type":"text","content":"Philips iFR technology","length":22,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":3000,"height":1908,"url":"https://media.zenfs.com/en/globenewswire.com/6aa3d54de29a9ec6dea2708452ee4836"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1iqTIfyZf.bRgpQPJr_14w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTYxMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6aa3d54de29a9ec6dea2708452ee4836","width":960,"height":611},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/NkTtzIEOwW5PktAw_83OcQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNTI2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6aa3d54de29a9ec6dea2708452ee4836","width":1200,"height":763}}},{"type":"text","content":"October 29, 2025","length":16,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"3-Year data from the largest global trial to date using Class I, Level A iFR in heart attack patients shows treating additional stenoses in the same procedure showed no significant difference in major outcomes compared with waiting for follow-up","length":245,"tagName":"p"}]},{"val":[{"type":"text","content":"Additional results from the ILIAS ANOCA study highlight the sustained benefits of physiology-guided assessment and tailored medical therapy for patients with angina and no obstructive coronary arteries","length":201,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":446,"olType":false},{"type":"text","content":"Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced late-breaking results from the iMODERN trial (Instantaneous wave-free Ratio Guided Multivessel Revascularisation During PCI for Acute Myocardial Infarction) at the Transc...